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 Abstract 
Many patients may present to Emergency Departments (ED) daily for a multitude 
of medical issues that may include chest pain, shortness of breath, nausea, vomiting, 
elevated troponin levels in the presence of CKD, abnormal serum BUN and creatinine 
levels, or an abnormal renal ultra sound.  Troponin levels that are elevated within the 
presence of CKD with no other signs and symptoms is not concerning for ACS or MI, but 
for cardiovascular death and mortality.   The purpose of this project was to develop, 
create and deliver an educational program designed to increase nursing knowledge of 
elevated troponin levels in the presence of Chronic Kidney Disease.  A pre-&post-test 
design was developed and implemented to measure the nursing staff’s knowledge of 
elevated troponin levels in the presence of CKD.  The educational program was designed 
as a pamphlet that provided information from the literature and relevant clinical 
experience about signs, symptoms and the diagnosis of CKD, signs & symptoms of 
Acute Coronary Syndrome, (ACS).  Twenty-three nurses (25%) completed both the pre-
test with a mean score of 74.7% with total scores ranging from 40%-90%.  Twenty-three 
nurses also (25%) also completed the post-test with a mean score of 76.5% with total 
scores that ranged from 50%-100% which helped to prove there was an overall increase 
in learning, therefore suggesting that nurses’ knowledge on the topic was improved.  
Recommendations and implications for APRNs are also discussed.   
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Troponin Elevation in Chronic Kidney Disease: An Educational Project 
Background/Statement of the Problem 
Chronic kidney disease (CKD) affects more than 30 million Americans with 
many going undiagnosed (Centers for Disease Control and Prevention, 2017).  The 
clinical manifestations of CKD are vague and often, the signs and symptoms are 
extremely non-specific and can manifest other disease processes.  The complications of 
CKD include hypertension, cardiovascular disease, hyperkalemia, elevated troponin 
levels at baseline (Mayo Clinic 2018).  These complications are enormous and 
tremendously intimidating, so it is imperative during the initial assessment that providers 
identify potential complications.   
According to Ozieh et al. (2017), CKD is defined as a decreased glomerular 
filtration rate of less than 60 ml/min, or the presence of one or more markers that indicate 
kidney damage for three months or greater.  CKD is not only burdensome as a medical 
disease, it is also very costly with non-dialysis CKD patients amassing a total of 18.2% of 
total Medicare expenditures which amounts to approximately 45.5 billion dollars 
annually, breaking down to approximately $22,348 per CKD patient annually.  Ozich et 
al. are the first to examine the costs surrounding CKD and the impact it has on the 
healthcare system as a whole.   
Patients who present to the emergency department with acute coronary syndrome 
(ACS) may have elevated troponin levels.  It also important to note is that patients who 
are not currently experiencing chest pain and have CKD can also present with troponin 
levels that are elevated.  Early detection and differential is imperative, so treatment may 
begin, which will help to prevent further progression to kidney failure.  Medical 
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professionals, including doctors, physician assistants, advanced practice registered nurses 
(APRNs) and nurses alike, need to emphasize primary prevention and treatment to 
preserve and restore health status and stave off disease progression.  
  Practicing clinicians and nurses alike should be acutely aware that during the 
evaluation of patients with CKD, the occurrence of potentially high sensitivity assays 
may result due to non-acute coronary syndromes.  Clinical and related medical 
professionals caring for patients with CKD need to keep in mind the increased risk of 
developing ACS or myocardial infarction (MI) directly related to acute ischemic heart 
disease in the CKD patient population. 
Troponin assays are used to diagnose potential ACS in all patients within the 
general population as well as those diagnosed with CKD and chronic renal disease.  The 
baseline troponin values in patients with CKD will likely be elevated above the ninety-
ninth percentile of the healthy population despite which troponin assay is utilized.  In 
patients with CKD, high sensitive assays for both troponin levels for T and I will display 
greater than the ninety-ninth percentile when the high sensitivity assays are utilized.  
Heart disease is the number one cause of death in the CKD patient population summating 
up to 50% of deaths Colbert et al. (2015). 
The purpose of this project was to develop, create and deliver an educational 
program to improve quality and increase knowledge of emergency department nurses on 
the significance of elevated troponin levels in the presence of CKD. The research 
question was: Do emergency room nurses understand the relationship with elevated 
troponin levels and patients with CKD?   An educational project was developed, created, 
and delivered to emergency department staff nurses to provide information about 
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troponin levels are elevated in patients with CKD without the presence of acute coronary 
syndrome (ACS).   
 
Next, the relevant literature review will be presented and discussed.   
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Literature Review 
A search of the literature was performed using the Cumulative Index to Nursing 
and Allied Health Literature (CINHAL) and (PubMed) using the search terms: cardiac 
troponin, troponin testing, CKD, estimated glomerular filtration rate, and acute 
myocardial infarction.  The review of literature was limited to full text articles only, 
published in English within the past ten years.   
Chronic Kidney Disease  
 According to Rosenberg (2016), CKD is defined as the presence of kidney damage. 
Kidney damage is detected as excretion of urinary albumin of greater than 30 mg/day or 
its equivalent.  A second identifier would illustrate decreased kidney function as an 
estimated glomerular filtration rate (eGFR) of less than 60ml/min/1.73m2 for a period of 
at least three months or more regardless of what caused the condition.  The damage or 
reduction of kidney function delineates CKD from an acute kidney injury (AKI).   
 Chronic kidney disease is classified into stages which guide providers on how to 
manage, locate any potential risks, guide treatment to cease progression, and highlight any 
potential complications that may arise from the progression of the disease.  Treatment 
involves reversing the causes of renal failure, preventing, or stunting the progression of 
renal disease, treating complications of renal disease, adjusting pharmacotherapy when 
appropriate to the current level of eGFR, and identifying and preparing the patient when 
renal replacement therapy will be mandatory (Rosenberg, 2016).  
Acute Coronary Syndrome 
 Miller & Granger, (2016) state that the chief complaint of chest pain is responsible 
for approximately 6 million annual visits to emergency departments in the United States.  
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Acute Coronary Syndrome (ACS) is responsible for 12 to 15% of those cases.  ACS is a 
functional term applied to patients where there is an indication of myocardial ischemia or 
myocardial infarction (MI).  There are three different types of ACS: unstable angina, non-
ST elevation MI, and ST elevation MI.  ST elevation and non-ST elevation MI, diagnosable 
if elevated troponin levels are present, which will typically rise and fall before, during, and 
after an event.  Unstable angina is classified as myocardial ischemia with no elevation in 
biomarkers like troponin.  Most often the clinical diagnosis is made based on the patient’s 
story, history of present illness, thorough physical examination, current electrocardiogram, 
evaluation of basic lab work, and or evidence of ischemia with stress testing (Miller & 
Granger, 2016).   
 The immediate focus should be on treatment, because early intervention leads to 
the best outcomes (Miller & Granger, 2016).  Upon presentation to the emergency 
department, an initial 12 lead EKG should be obtained within ten minutes, and continuous 
telemetry monitoring initiated.  Next, a history and physical exam to correlate with current 
signs and symptoms exhibited.  Laboratory tests should be ordered, to include troponin, 
electrolytes, bun, creatinine, and complete blood count.  A chest x-ray is standard in this 
patient population, as it can be an asset with differential diagnosis. A risk stratification 
assessment of the patient presenting with these signs and symptoms is conducted (Miller 
& Granger, 2016). 
Troponin Sensitivity and the Correlation to CKD & ACS 
Troponin is the preferred biomarker to diagnose acute myocardial infarction 
which may or may not be present with presentation of ACS.  Troponin is a 
macromolecular complex that consists of three polypeptides closely intertwined and are 
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actively related to the contraction of heart muscle.  The three types of troponin are cTnC 
which are responsible for calcium binding, cTnI for inhibiting actin-myosin collaboration 
and lastly cTnT which represents tropomyosin that is required to enable contraction 
(Mohammed & Januzzi, 2010).   
 According to Mohammed & Januzzi, (2010), troponin is discharged when 
irreparable damage to the myocyte is about to occur.  Quantifiable release of troponin 
begins typically 4-6 hours after cell death, and crests at approximately eighteen to 
twenty-four hours. Troponin levels can remain detectible in serum levels for the 
subsequent fourteen days post event. Typically, troponin levels are drawn at specific 
intervals every three, six, or eight hours depending on policy of each individual 
institution (Mohammed & Januzzi, 2010).   
The elevation of troponin can occur without the presence of ACS Mohammed & 
Januzzi, (2010).  The authors identify a multitude of causes for the potential rise in 
troponin without the presence of ACS in their review that encompassed mainly 
quantitative research from eight studies.  The elevation should be thoroughly investigated 
and not be discarded as a “false positive.”  The authors concluded that the adoption of the 
99th percentile of a healthy patient population to diagnose MI.  With newly available 
ultra-sensitive blood testing methods in place and the increased use in patient care, the 
conclusion will be an increase in troponin levels in patients presenting without the 
presence of ACS.  The authors caution providers that the elevation of troponin does not 
identify the mechanism of myocardial injury and addresses the importance of utilizing 
differential diagnosis for the elevated troponin value.    
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Wang, et al. (2017) conducted a review of current literature searching several 
databases for evolving biomarkers now available, and those that are considered up and 
comers within the realm of myocardial necrosis.  The authors reviewed studies on high 
sensitivity reactive protein (hsCRP) and noted an association between elevated 
inflammation levels and potential cardiac events with hsCRP being a predictor of these 
events.  The researchers reviewed 55 studies and analyzed other evolving biomarkers that 
included natriuretic peptides, troponins, uric acid, and galectin-3 all of which show 
correlations with cardiovascular events. Cardiac troponin I (cTnI) and T (cTnT) are 
proteins that are exclusive to myocardial function and are extremely sensitive biomarkers 
that signify damage to the myocardium upon their release (Wang et al., 2017).  
Furthermore, troponins are classified as the most sensitive biomarkers indicating 
myocardial injury perpetually more than its creatinine kinase counterpart.  The 
researchers looked at a variety of biomarkers, including troponin, natriuretic peptides, 
and amino acids, that may be indicative of myocardial injury.  The authors conclude that 
more research is needed to further apply the newer biomarkers that will proliferate 
rapidly.  These biomarkers should not be exclusively acted upon, rather that they be 
utilized in conjunction with other clinical information to include thorough history, 
physical, and risk stratification along with radiographic findings to accurately treat and 
diagnose patients.   
Van der Linden et al. (2016), conducted a meta-analysis aimed to quantify and 
compare the relationship between cTnT and cTnI troponin levels with cardiovascular and 
all-cause mortality in the general population. The researchers’ analysis included 2585 
reviewed citations, 11 studies, with data on 65,019 participants.  Random pooling 
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illustrated substantial relations between basal cardiac troponin levels and all-cause 
mortality.  There was a significance in the difference of the meta-regression analyses for 
cardiovascular mortality but showed no statistical difference for all-cause mortality 
(P<0.01).  The authors concluded that an elevation of baseline cTnT and cTnI show 
strong links for an increased risk of cardiovascular and all-cause mortality during follow 
up in the general population.  The correlation is even stronger for cardiovascular 
mortality than all-cause mortality, but that troponin T is stronger than troponin I but will 
require further research.   
Jaffe & Morrow (2017) delineate between the use of cTnI, and cTnT.  The authors 
describe the assays as being sensitive, and that higher sensitive assays are available, but 
not in the United States.  Jaffe & Morrow highlight guidelines for troponin testing and list 
a variety of clinical conditions where it is essential to include possible acute myocardial 
infarction, ACS, after revascularization therapy, and after myocardial infarction which 
can help determine the magnitude of the infarct and prognosis.  The initial troponin level 
is drawn upon presentation to the health care system and typically re-drawn and 
compared to the initial result within three to six hours depending on facility policy.  In 
the general population, there is even a small window where elevated troponins can be 
measured without an acute event, and the typical rise and fall of troponin will not be seen 
in this population.  Troponin is the preferred biomarker to aid in the diagnosis of 
myocardial cell damage or death as seen with myocardial infarction.  Values that register 
above the 99th percentile in the healthy population and in conjunction with clinical 
information and electrocardiographic changes seen on EKG may be because of structural 
heart damage without any acute presentation.  The more sensitive the assay, the more 
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vital to investigate if the troponin level has changed which can assist in the confirmation 
of myocardial infarction.  The recommendation of the authors is to use troponin as 
preference to creatinine kinase MB both for diagnostic and prognostic means, as it is not 
cost-effective care to obtain both. 
Gibson & Morrow (2017) discuss the possible causes of troponin release in the 
absence of ACS. The authors found in one study that several patients with specific 
conditions may cause patients to present with elevated troponin levels to including 
tachycardia (28%), pericarditis (10%), heart failure (5%), no clear precipitating event 
(47%), and even participating in strenuous exercise, (10%).  Several other studies were 
included in the review to include an additional 6 studies with a combined sample size of 
54,000 study participants and confirmed that a small amount of elevated troponin levels 
can be linked to structural heart disease in the absence of any acute process. When these 
authors reviewed troponin levels in patients with stable ischemic heart disease, an 
additional 6 studies with a combined sample size of 19,560 it was found that elevated 
troponin levels were associated with irregularities of cardiac structure and functionality 
nearly 37% higher, and in cases of critical illness a worse prognosis was highly probable. 
The authors’ state that troponin elevation without ACS is a significant finding and that 
further work up may be justified solely on that finding.  Uncovering the underlying cause 
of the troponin elevation through a comprehensive history and detailed physical 
examination, which can illuminate conditions, like myocarditis, pericarditis, cardiac 
contusion, sepsis, pulmonary embolism, and heart failure, is essential.    
Gibson & Morrow, (2017) state there is currently no data from randomized trials 
that indicate that there is a reduction of risk from current therapeutic regimens for 
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patients with troponin elevations without the presence of ACS. The authors recommend 
the use of aspirin unless contraindicated because it is generally harmless, though the use 
of antiplatelet and antithrombotic medications are not generally used in the management 
of elevated troponin.  Lastly, troponin is an essential part of the decision-making process 
in the setting of other illnesses like pulmonary embolism, and cardiotoxic 
chemotherapeutic medication administration.   
Chronic Kidney Disease and its Relationship to Coronary Heart Disease 
Matsushita et al., (2016) conducted a systematic review in order to clarify the 
clinical guidelines on the application of predicting the cardiovascular risk of those 
diagnosed with CKD.  Matsushita et al completed an individual level meta-analysis 
where a creatinine based glomerular filtration rate (eGFR) and albuminuria were used as 
measures for CKD and applied the precise statistical methods across 24 cohort studies.  
The meta-analysis showed that eGFR and albuminuria help to improve the prediction of 
risk of getting cardiovascular disease over outdated risk factors to include coronary heart 
disease, eGFR, and high-density lipoprotein (HDL) for overall mortality and heart failure. 
In summary, the two key measures eGFR and albuminuria improve CVD risk estimates 
beyond traditional risk factors.  It is felt that clinical guidelines may require updates 
about how or when to integrate CKD measures and other mentioned biomarkers in 
prediction of CVD based on outcomes desired in a specific population and the 
accessibility of needed biomarkers in the CKD population Matsushita et al., (2016). 
Sud & Niamark (2015) conducted a systematic review with the purpose of 
advancing the understanding of cardiovascular outcomes in patients diagnosed with 
advanced or progressive CKD.  The authors reviewed data from five articles from the 
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United States and Canada with a focus on describing the dynamics of cardiac death in 
patients with CKD.  The results of the review showed that when eGFR is below 
60/ml/min, cardiovascular disease is the most common cause of death (Sud & Niamark, 
2015).  Patients with advanced CKD are excluded from clinical trials for heart failure 
therapy.  The researchers conclude that the risk of sudden cardiac death is elevated in 
patients with systolic heart failure as ejection fraction decreases.  Renewed calls for 
increased coordination of efforts among nephrologists and cardiologists to start 
randomized controlled trails devoted solely to patients with advanced CKD can help to 
improve outcomes and understanding of the disease pathophysiology (Sud & Niamark, 
2015).  
Sarnack, Gibson & Henrick (2015) conducted a systematic review on the 
correlations between CKD and coronary heart disease.  A diminished glomerular 
filtration rate and increased proteinuria raise the potential to develop cardiovascular 
disease in populations with elevated cardiovascular risk.  The authors reviewed a 
combination of ten studies which varied from meta analyses, two randomized controlled 
trials, and one longitudinal study.  Sarnack, Gibson & Henrick, (2015) recommend a 
thorough risk stratification assessment with the addition of statin medication to reduce 
cholesterol in patients with eGFR less than 60ml/min per 1.73 m2.  A commitment to the 
reduction of hypertension in patients with proteinuria and CKD with the use of an 
angiotensin blocker is recommended (Sarnack, Gibson & Henrick 2015).  The studies 
concluded that decreased eGFR and increased proteinuria increase the risk of developing 
cardiovascular disease.  In addition, patients diagnosed with CKD will require drug 
dosage adjustments because of the potential for drug related adverse effects.  Patients 
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diagnosed with CKD present with traditional and nontraditional risk factors that 
contribute to the development of cardiovascular disease such as hypertension, smoking, 
diabetes, and elevated cholesterol levels (Sarnack, Gibson & Henrick, 2015). 
Cardiac Biomarkers in CKD without ACS 
 Lamb et al., (2007) conducted an observational cohort study that enrolled two 
hundred and twenty-seven Caucasian patients at East Kent Hospital located in Oxford, 
United Kingdom. The purpose was to evaluate the prevalence of increased cTnI 
concentrations in patients diagnosed with CKD to determine clinical associations and the 
prognostic importance of increased cTnI Ultra assays compared against cTnT and the 
original cTnI standards. Participants were grouped into CKD stages according to the 
eGFR using estimated glomerular filtration rate (eGFR) and the simplified Modification 
of Diet in Renal Disease Study formula.  In conclusion, the researchers illustrate that 
cTnI concentrations are elevated in patients with CKD, although the cause is still unclear 
(Lamb et al., 2007).   
deFilippi et al., (2012) conducted a multicenter observational study to analyze the 
association between high sensitivity (cTnT), and (cTnI), in patients with cardiovascular 
disease and stable CKD.  The study was conducted in outpatient nephrology clinics at 
three hospitals.  The sample size was 148, all males, ages 18-71 years who had prior 
myocardial infarction, coronary revascularization, glomerular filtration rate less than 
60ml/min, an echocardiography measuring left ventricular ejection fraction, and CT scan 
to assess level of coronary artery calcification. Patients with CKD had a high sensitivity 
assay troponin T (deFilippi et al., 2012). The association of high cardiac troponin assays 
and renal function, specifically the troponin T marker, was significantly higher than that 
13 
of its troponin I counterpart (deFilippi, et al., 2012).  Conclusively, when troponin is used 
to confirm suspected acute coronary syndromes in patients diagnosed with CKD, the 
baseline value should measure above the 99Th percentile of the healthy population. 
 Balamuthusamy et al., (2007) conducted a retrospective chart analysis with a 
sample size of 108 patients that underwent coronary angiography.  The study took place 
over a period of three years at the Mount Sinai Medical Center located in Chicago, 
Illinois.  The goal was to analyze sensitivity and specificity of cardiac troponin I in 
detecting obstructive coronary artery disease in the African American population 
diagnosed with renal insufficiency.  Participants were of African American decent, 
diagnosed with acute coronary syndrome and had some degree of renal failure, namely 
creatinine levels elevated >1.1mg/L.  The authors found that cTnI has lower sensitivity 
and specificity in patients with renal failure undergoing hemodialysis secondary to 
changes in elimination.  They also conclude that other methods should be used to arrive 
at the correct diagnosis and appropriate risk stratification of patients with non-ST 
elevation myocardial infarction.  Further research is essential to understand results of 
traditional biomarkers used for diagnostic reasons (Balamuthsamy et al., 2007). 
Colbert et al., (2014) conducted a review that aimed to summarize fifty-one 
completed studies of varying design primarily cross sectional and longitudinal study 
designs with one study being a case control design.  The researchers reported associations 
among used cardio biomarkers like cTnT, B-type Natriuretic Peptide (BNP), NT-Pro-
BMP, left ventricular mass index, coronary artery calcium score (CAC), carotid intima-
media thickness (cIMT), and clinical outcomes in patients with CKD in patients not 
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undergoing maintenance dialysis to highlight the strengths and limitations of data that is 
currently available for use with prognostication.   
  Colbert et al., (2014) conclude their review stating that there are current 
knowledge gaps and more data is needed before these biomarkers can be reliably used in 
the population of patients with CKD.  Colbert et al., (2014) state that some of the 
observational studies reporting associations between cTnT and a decline in eGFR in non-
dialysis patient populations with CKD may be affected by a decreased renal clearance in 
the setting of advanced CKD.  While the results signify that these biomarkers can be used 
to forecast future cardiovascular events in asymptomatic patients with CKD, additional 
research is needed to confirm a standardized cutoff value for biomarkers as diagnostic 
tests for patients with CKD. 
Prognostic Value of Cardiac Markers in CKD 
Michos, et al., (2014) conducted a large systematic review & meta-analysis with 
the purpose to review literature on troponin testing in patients with CKD without the 
presentation of ACS.  Approximately 98 studies in 105 publications met the inclusion 
criteria.  Michos et al., (2014) state that further work is needed to determine the 
mechanism for the link between elevated troponin levels and undesirable outcomes.  It 
was also established by these researchers that more research is needed to investigate 
whether it is solely the troponin level alone, or its presence in combination with other 
biomarkers that can improve the way CKD patients are positioned in higher and lower 
risk groups in existing clinical models. The question still remains of how patients with 
CKD with risk stratification performed by troponin level for dialysis patients with no 
presentation of ACS their clinical course of treatment. In the conclusion of this review, 
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the researchers show that elevated troponin levels reveal an association of a worse 
prognosis in patients with CKD not experiencing ACS.  For patients with CKD with no 
indication of ACS, elevated troponin levels remain potent predictors of mortality, and 
currently support the current U.S. Food and Drug Administration position that measuring 
serum troponin levels is an appropriate risk stratification tool in this patient population. 
 Bueti et al., (2006) completed a study utilizing a retrospective cohort design that 
enrolled a total sample size of 149 at St. Boniface General Hospital, Winnipeg, Canada 
that aimed to examine the association between troponin I levels and 30-day outcomes.  
All patients were evaluated according to their chief complaint, risk factors for cardiac 
disease, initial troponin level, and any other major cardiac event to include MI, 
cardiovascular death, or coronary revascularization.  Bueti et al., (2006) determined that 
the troponin level was commonly analyzed in acutely ill patients that presented to the ER. 
The results showed that troponin I was associated with an adverse 30-day outcome 
despite the clinical presentation.    The chief concern or nature of presenting complaint 
was not helpful in determining if a major cardiac event (MCE) was going to occur within 
30 days.  It was found that troponin I with a level of > 0.3 ng/L was strongly correlated to 
MCE, in fact a level of greater than >2.0 supported the data and was predictive of MCE 
>25% of the time.  Troponin level elevated above >0.3 are clinically significant in 
patients undergoing dialysis regardless of their clinical presentation. 
 In a pilot study conducted by Sukonthasarn & Ponglopisit., (2007) researchers 
aimed to find the diagnostic level and rising pattern of cardiac troponin T (cTnT) with 
patients diagnosed with chronic renal dysfunction presenting with acute myocardial 
infarction.  The study design was a pilot cross sectional study with a sample size of 46 
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that compared troponin T levels in adult patients with chronic renal dysfunction that were 
subsequently admitted and later found to have acute myocardial infarction with age and 
sex controls and non-coronary diagnosis.  Researchers concluded that troponin levels of 
0.1 ng/ml drawn in the first 24 hours of admission proved to be diagnostic for AMI in 
patients with chronic renal dysfunction.  Participants were then redrawn at subsequent 
intervals 6, 12, and 24 hours post initial draw.  Sensitivity and specificity of troponin 
levels were greater if chronic renal dysfunction patients were excluded.   
Relationships between Elevated Cardiac Markers in CKD without ACS 
 Alam et al., (2013) authored a research article that aimed to examine the 
association of elevated troponin I levels in stable patients undergoing maintenance 
hemodialysis therapy with cardiac-specific mortality, and to distinguish if any increased 
risk was autonomous of inflammation status.  The design utilized a cohort observational 
study, plasma troponin I levels were drawn with routine pre-dialysis lab work with C 
reactive protein.  All patient outcomes were closely monitored and determining all deaths 
as cardiac or non-cardiac.   
 The study’s design was that of an observational single-center cohort with a 
sample size (N=133), featuring participants classified as chronic, stable non-hospitalized 
hemodialysis patients where monitoring took place for a three-year period beginning in 
July/August 2009 and followed until July of 2012.  The blood tests were drawn in the 
hospital’s hemodialysis unit and analyzed in the hospital’s central laboratory.  Alam et 
al., (2013) conclude that elevated troponin I levels provide prediction of cardiac risk.  
Elevated troponin levels are life-threatening, and it is essential to get to the underlying 
pathophysiological progressions that lead to it.  The study adds to the research currently 
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available to back more extensive tactics to conduct more thorough cardiac risk 
stratification in hemodialysis patients to include stress testing, targeted risk stratification, 
functional cardiac testing, or conventional medical treatment.   
 Chen et al., (2013) conducted a study that aimed to assess the results of 
troponin I in non-acute coronary syndrome patients with a diagnosis of CKD.  The study 
was constructed using a sample size of N= 293 patients with CKD and had a troponin 
level drawn. The design of the study was shown through retrospective chart review over a 
two-year period.  The results of the study concluded that almost half, 43.34% of the non-
acute coronary syndrome patients with CKD, and 26.03% of the patients without ACS 
and CHF have elevated levels of troponin I.  Furthermore, congestive heart failure is 
linked to elevated troponin levels without the presence of ACS patients with CKD.   
In a study, Li, et al., (2015) performed a meta-analysis through a systematic 
search of studies pertinent published by November 2013 in the MEDLINE database. 
Studies were included based on 5 inclusion criteria that included published in English, 
had randomized control trials or observational study design, patients diagnosed with 
CKD defined as having eGFR <60/mL/min per 1.73m2, had stated long term all-cause 
mortality or cardiovascular mortality of CKD, patients who had elevated levels of C-
reactive protein (CRP), and had estimates of risk ratios (RR’s) or Hazard ratios (HR’s) 
within a 95% confidence interval.  Exclusion criteria included animal studies, autopsies, 
phantom studies, and myocardial infarction.  A total of 828 articles were returned and 
after excluding many, it was decided that 20 would be included in the C-reactive protein 
(CRP) analysis, and 17 would be included within the troponin analysis.   
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In conclusion, the meta-analysis shows elevated troponin levels and CRP are 
largely associated with increased risks of all cause and cardiovascular mortality in 
patients diagnosed with CKD.  Future studies with more strict calibration, long term 
monitoring, and more complex design representing large and representative populations 
are essential to the investigation of more complex risk stratification of CKD patients.   
 Next, the Theoretical Framework guiding this project will be introduced and 
discussed.  
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Theoretical Framework 
Two separate frameworks were identified and discussed for use in this project.  
The Adult Learning Theory was developed by Malcom Knowles in the beginning of the 
1970’s and will assist in the development and delivery of an educational program.  
Knowles’ learning theory was created specifically for adults and is largely formulated on 
six individual principles: the need to know, the learners’ self-concept, the role of the 
learner’s experiences, the learners’ readiness to learn, orientation to learning, and lastly 
the learners’ motivation to learn (Knowles, Holton, & Swanson, 2011).  Adults are 
intuitive and seek what the reason is before learning something new.  Self-concept is 
explained as being responsible for their own decisions and being capable of self-
direction.  The role of learners’ experiences relies on experimental techniques that delve 
into the experience of the learner utilizing experiences like group discussions, simulation 
exercises, and peer to peer helping of one another.  Readiness to learn highlights the 
learners’ the ability to accomplish what essentially needs to be done so knowledge can be 
attained.  Orientation to learning occurs based on the perception that lessons being taught 
will help them to problem solve with real life situations.  Motivation directly relates to 
the adults’ responsiveness to internal like increased job satisfaction, and external 
motivators like promotions and better salaries (Knowles et al., 2011).  
Malcom Knowles Adult Learning theory is applicable to this project primarily 
with the principle of Andragogy which translated means “Man Leading.”  The use of 
Knowles Adult Learning Theory will allow nurses to learn at their own pace, at a time 
and place convenient to them.    Adults are primarily lifelong learners and typically 
participate actively especially in the field of medicine, knowing it will translate into being 
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better prepared healthcare workers.  Nursing is no different and requires individuals to 
keep up with current best practices to maintain core competencies with specificity to their 
nursing specialty.  If a nurse discovers a lack of experience with a skill or procedure, they 
will typically obtain the information needed to complete the task via textbook, resource 
material or from another college.  Registered nurses are more compelled to learn when it 
will directly benefit their way of clinical practice (Knowles et al, 2011).    
The Kellogg Foundation’s Logic Model was implemented to assist in the 
preparation, execution, and evaluation of the educational program that was developed by 
the researcher. According to the Kellogg Foundation (2004), the Logic Model provides a 
systematic and visual way to present and share the understanding of relationships among 
the resources available, operate the program, the activities planned, and the change or 
results anticipated to achieve.  The Logic Model is comprised of five components that are 
visually depicted on a diagram and are read left to right.  The five components included 
are resources/inputs and activities which are fall under the umbrella of the researchers 
planned work.  The remaining components fall under the researchers intended results and 
include outputs, outcomes, and impact.   
The Logic Model will be utilized in this project implementation.  The inputs in 
the project would be support from emergency department management and the Chief 
Nursing Officer.  The activities would be the educational information provided to ER 
nurses in both the poster displayed and the pamphlet emailed to participants.  The 
outcomes associated with the project would be an overall knowledge increase after the 
informational program has been delivered.  The impact of the project would be an 
increased awareness and understanding for elevated troponin levels in the setting of CKD 
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without ACS.  Learning will be assessed by the administration of a 10 question pre-and 
post-test.  The Logic model is illustrated below (Figure 1).  
Figure 1.  The Logic Model retrieved from https://www.wkkf.org/resource-
directory/resource/2006/02/wk-kellogg-foundation-logic-model-development-guide  
 
Next, the methods used to conduct this project will be presented and discussed.   
  
22 
Methodology 
Purpose/Question:   
The purpose of this project was to develop, create and deliver an educational 
program to improve quality and increase knowledge of emergency department nurses on 
the significance of elevated troponin levels in the presence of CKD.  The research 
question was: Do emergency room nurses understand the relationship between elevated 
troponin levels and patients with CKD?  
Design: 
 An educational program was developed of to determine ED nurses’ knowledge on 
the significance of elevated troponin levels in the presence of CKD.  A quantitative pre-
test and post-test format (Appendix A) was instituted to adequately measure the 
emergency department nurses’ knowledge of elevated troponin levels in the presence of 
CKD.   
Site:   
 The proposed project was conducted at a local community teaching hospital with 
359 acute care beds located in Warwick, Rhode Island.  The Emergency Department has 
60 beds with an annual patient census of approximately 70,000 and is Rhode Island’s 
only Level 2 Trauma Center.   
Sample Size/Participants: 
The study sample was selected using a purposive random sample.  The total 
possible participants was 92 nurses.  The target proposed sample size consisted of one 
third or 33% registered nurses actively working within the emergency department to 
include full time, part time, per diem and traveler status (n=32).  Inclusion criteria 
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consisted of staff registered nurses (RN’s) assigned to the ER, with no exclusions based 
on age, gender, ethnicity, educational level, or employment tenure.  Exclusion criteria 
was nurses floating to the emergency department for supplemental coverage, or those 
RNs not directly assigned to the ED, and non-nursing personnel.   
Procedure: 
 Emails were sent to the Chief Nursing Officer and the Director of Emergency 
Services to garner support for the proposed project.  Email responses were received by 
this author from the Chief Nursing Officer (Appendix B) as well as the Director of 
Emergency Services granting permission for the project, on a condition that the 
Institutional Review Board (IRB) at Kent County Hospital also approved it. IRB 
applications were submitted to both Kent County Hospital and Rhode Island College.  
Kent County Hospital IRB determined that this project was exempt from IRB approval 
(Appendix C).  Rhode Island College IRB approved this application.   
The anticipated timeframe for the project was sometime in February and March of 
2018 in the Emergency Department at Kent Hospital in Warwick, Rhode Island.  An 
informational email (Appendix D) and email script (Appendix E) was sent to the Director 
of Emergency Services, shift managers, as well as all nursing staff to explain the purpose 
of the project before the educational information was delivered.  The staff was informed 
that participation is voluntary. An incentive for participation was a gift card in the 
amount of twenty-five dollars.  A time allotment of two weeks was allowed to take the 
pre-test (Appendix A) which was anonymously completed via an online survey platform 
called Survey Monkey.  Reminder emails (Appendix E) were sent out to potential 
participants five and ten days after the pre-test was sent.  The educational pamphlet 
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(Appendix F) was developed with the help of the literature and the clinical experience 
and expertise of this program developer.  The use of educational pamphlet (Appendix F) 
allowed the material to be viewed via email or in person as it was placed in the break 
room for staff to review during breaks or meal times.  Reminder emails to review the 
educational pamphlet (Appendix F) and complete the post-test were sent five and ten 
days after the educational pamphlet (Appendix F) was sent.  The pre-& post-test was 
anonymously completed via an online survey platform called Survey Monkey one week 
after potential participants had time to review the educational pamphlet (Appendix F).  
The pre-and post-tests (Appendix A) were analyzed for an overall increase in knowledge 
across the board for all nursing staff that participated.  The learning objectives are listed 
below in Table 1. 
Table 1. 
Objectives Content 
The Nurse will be able to demonstrate 
knowledge pertaining to signs and 
symptoms of CKD. 
 Common Signs & Symptoms of CKD 
The Nurse will be able to identify risk 
factors for CKD. 
 Risk Factors for CKD 
The Nurse will be able to describe how 
CKD is diagnosed. 
 Diagnosis of CKD 
The Nurse will be able to demonstrate 
understanding of common signs and 
symptoms of ACS 
Common Signs & Symptoms of ACS 
The Nurse will be able to state risk factors 
for ACS. 
Risk factors for Acute Coronary Syndrome 
The Nurse will be able to identify both 
normal & abnormal troponin levels 
Normal Troponin Levels 
The Nurse will be able to explain the 
significance of elevated troponin levels in 
the setting of CKD 
How the nurse should respond with 
elevated troponin levels in the presence of 
CKD, but with the absence of Acute 
Coronary Syndrome 
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Measurement: 
 A pre-test and a post-test were developed based on the information to be delivered 
(Appendix A).  The project consisted of a design of quantitative data encompassed in the 
survey.  The project compared nurses’ responses from the pre-test-to the post-test which 
occurred after information on the topic has been presented.   Comparison was 
accomplished through standard statistical analysis to include total scores, mean scores, 
and percentiles taken directly from the number of respondents.  The pre-test and post-test 
(Appendix A) consisted of the same exact identical questions and was piloted with Rhode 
Island Collage Master’s Program students for accuracy, clarity, and ease of understanding 
prior to use within the educational program There was no identifiable demographic data 
collected. 
Data Analysis 
 The data collected from the pre-tests and post-tests (Appendix A) were analyzed 
using descriptive statistics to include total scores, mean, and percentages.  
Next, results will be presented and discussed. 
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Results 
 Out of the possible total number of 92 RN’s working within the Emergency 
Department at the time of the development and implementation of this informational 
program, 23 respondents completed the pre-test (Appendix A) (25.0 %).  The respondents 
were categorized by educational level, and years of experience.  Ten respondents held 
associate degrees (43.5 %) and 13 held bachelor’s degrees (56.5 %). No RN’s with 
diplomas or advanced degrees responded in the pre-test.  Of the respondents, there were 
three nurses with less than 5 years’ experience (13.0%), four nurses with between 6 and 
10 years’ experience (17.4%), eight nurses with between 11-15 years of experience 
(34.8%), and eight nurses with over 20 years’ experience (34.8%).  
Nurse participants in the program completed a pre-test, and post-tests (Appendix 
A).  The question types were multiple choice or select all that apply. The completed pre-
tests scores ranged from 40% to 90% with a mean score of 74.7%.  Roughly 21.7% of the 
nurses (n=5) scored ninety percent on the pre-test, 30.4% (n=7) scoring in the eightieth 
percentile, 30.4% (n=7) scoring in the seventieth percentile, 13.0 (n=3) percent scoring in 
the sixtieth percentile, and lastly 4.3% (n=1) scoring in the fortieth percentile.   
The number of nurses that completed the post-test (Appendix A) was also (n=23).  
The respondents were categorized by educational level, and years of experience.  Those 
with associate degrees were 4 respondents, (17.2%), bachelor’s degree, 18 respondents 
(78.3 %). One respondent has a master’s degree which represented (4.4%). No 
respondents with diploma certificates responded to the post test. Of the respondents there 
were eight nurses with less than 5 years’ experience (34.8%), five nurses with between 6 
and 10 years’ experience (21.8%), one nurse with between 11-15 years of experience 
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(4.4%), and eight nurses with over 20 years’ experience (34.8%).  All the respondents got 
question 3 incorrect which asked how CKD is diagnosed and was a multi response 
question requiring participants to pick more than one answer.   
The completed post-test (Appendix A) scores ranged from 50% to 100% with a 
mean score of 76.5% therefore demonstrating an overall increase in learning.  Two of the 
questions (questions 4 & 5) asked the participants if they could identify normal 
glomerular filtration rate in a healthy adult and risk factors for CKD. There was no 
change in the score on these questions.  One question of note experienced a significant 
decline from the pre-test to the post-test (question 11).  The question asked participants 
what the significance of an elevated troponin level meant in the presence of CKD with 
the absence of presenting notable cardiac symptoms.  Participants responded correctly 
52% of the time (n=12) on the pre-test and only 17% (n=4) on the post-test regardingM 
question 11.   Question 3, which asked how CKD is diagnosed improved from 0% correct 
on the pre-test to 65% (n=15) correct on the post-test.  Most of the nurses were able to 
correctly identify the appropriate signs & symptoms of ACS in both the pre-test 91.3% 
(n=21) and post-test 95.6% (n=22).   
          
Figure 1.  Pre-Test & Post-Test Results by Question, n= 23 
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Next., the summary and conclusions will be presented and discussed. 
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Summary and Conclusions 
Chronic kidney disease (CKD) affects more than 30 million Americans with 
many going undiagnosed (Centers for Disease Control and Prevention, 2017).  The 
clinical manifestations of the disease are common and often the signs and symptoms are 
extremely non-specific and can manifest other disease processes.  The complications of 
CKD are vast, and tremendously intimidating, so it is imperative during the initial 
assessment that providers identify potential complications.  CKD is not only burdensome 
as a medical disease, it is also very costly with non-dialysis CKD patients amassing a 
total of 18.2% of total Medicare expenditures which amounts to approximately 45.5 
billion dollars annually, breaking down to approximately $22,348 per CKD patient 
annually. 
A review of current relevant literature was conducted, and models were selected 
to guide this project to include the Logic Model, and The Adult Learning Theory. The 
purpose of this project was to develop, create and deliver an educational program to 
improve quality and increase knowledge of emergency department nurses on the 
significance of elevated troponin levels in the presence of CKD.  
The design was the development of an educational program to determine ED 
nurses’ knowledge on the significance of elevated troponin levels in the presence of 
CKD.  A quantitative pre-test and post-test format (Appendix A) was instituted to assess 
the emergency department nurses’ knowledge of elevated troponin levels in the presence 
of CKD.  The twelve question pre- & post-test (Appendix A) was developed by this 
program developer and was piloted to demonstrate ease of use and understandability.  ER 
nurses were asked to complete a pre-test, read an educational pamphlet (Appendix F) and 
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then take a post-test. The pre and post-test (Appendix A) were distributed through online 
survey platform of Survey Monkey. An invitation with a link to the survey was emailed 
nurses via their work email (Appendix E).  After the pre-test was completed, an 
educational packet was emailed, and a hard copy was placed on bulletin boards in the 
break room within the emergency department for the nurses to review at their 
convenience.   
The identified target population for this educational program was 92 nurses who 
actively work in the Emergency Department at Kent County Hospital in Warwick, Rhode 
Island. A total number of (n=23) or 25% completed both the pre-test and post-test with 
mean scores of 74.7 and 76.5 respectively.  One question of note experienced a 
significant decline when the pre-test was compared to the post-test (question 9).  
Question 9 asked participants the what significance of an elevated troponin level meant in 
the presence of CKD, with the absence of presenting notable cardiac symptoms. 
Participants responded correctly 52% of the time (n=12) on the pre-test compared to just 
17% (n=4) on the post-test.   The most improved score came on question (question 5) 
which refers to how CKD is diagnosed.  On the pre-test, all of the nurses thought that 
CKD was diagnosed analyzing serum BUN and Creatinine results, not realizing there are 
two other diagnostic tools that aid in the diagnosis which are renal ultra sounds, and 
microalbumin levels.   
Limitations to the project included a low response rate. The goal was to have 33% 
of the possible 92 nurses respond (n=33).  The response rate was only 23%.  The lack of 
participation can potentially be tied to an increase in patient acuity, census and missed 
meal breaks at the time of implementation, and as a result a lack of time to complete the 
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pre-test, educational packet, and the post-test.  Another identified limitation was lack of 
time to complete the pre-test, educational packet, and post-test which resulted in the 
initial allotment of two weeks to be extended into three weeks to garner the most 
participants.  The method of announcing the project could be identified as a potential 
limitation.  Nurses receive countless emails daily and the possibility exists that emails 
about this program were skipped over or deleted in error even though there was 
enthusiasm and support for the educational program.  Many nurses do not check their 
work email from home.  Respondents in the post-test included one APRN and four 
Associate degree nurses which could have altered the results.  Another limitation 
involved some participants not completing all of the questions on the pre or post-test 
which resulted in those responses having to be discarded. 
The main objective of this educational program to improve knowledge of nurses 
in the emergency department was met. There was an increase in overall learning by about 
1.8% as illustrated in the pre-& post-test mean scores.   
Next, Recommendations and Implications for Advanced Nursing Practice will be presented 
and discussed. 
  
32 
Recommendations and Implications for Advanced Nursing Practice 
 Advanced Practice Registered Nurses (APRN’S) now more than ever will be 
called upon to be a more active player in the United States Healthcare System as a change 
agent and leader when it comes to advocating for patients and providing care.  For 
APRN’s working in any setting, it will be essential for them to discern between the 
patient that presents with an elevated troponin in the presence of CKD versus the patient 
that presents with an elevated troponin and the constellation of signs and symptoms 
concerning for ACS with or without the presence of CKD.  The APRN will begin to 
stratify the patient’s risk more comprehensively to identify potential incidences of 
increased risk like that of the troponin level, but the emphasis of future research should 
be placed on understanding the pathophysiological processes that precede troponin 
elevation in the CKD patient population Alam, et al. (2013).   
 Furthermore, the APRN that quantifies patient risk using CKD measures like 
eGFR and albuminuria will help to improve cardiovascular disease risk prediction far 
beyond traditional risk factors resulting in better metrics as they have already been 
measured in most CKD patients Matsushita et al., (2016).  Patients with CKD that present 
without suspected ACS can present with elevated troponin levels represent a more potent 
predictor of mortality Michos, et al. (2014).  The APRN, along with nurses and other 
members of the healthcare team, should respond appropriately when any patient presents 
with symptomology concerning for ACS such as chest pain, shortness of breath, nausea, 
vomiting, pain that radiates to the jaw, arm, back, or the epigastric area.   
The APRN should position themselves at the bedside to gather the history of the 
present illness, background information, and a complete physical examination.  The next 
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steps would involve the implementation of diagnostic testing like an EKG, appropriate 
lab tests to include Complete Blood Count, Basic Metabolic Profile, Brain Natriuretic 
Peptide (BNP), Procalcitonin, Pro Thrombin Time (PT), Partial Thromboplastin Time 
(PTT), INR, Creatine Phosphokinase (CPK), C-Reactive Protein (CPK), Arterial Blood 
Gas (ABG), as well as developing an appropriate working list of dynamic differential 
diagnoses that will cast a wide net to ensure nothing will be overlooked.   In many cases, 
the above events will be taking place simultaneously to provide the most effective and 
appropriate treatment modalities to ensure the best outcome for the patient.   At this 
crucial point in the patient’s care, it will be up to the APRN and multidisciplinary team to 
determine if troponin elevation identifying as true myocyte necrosis, or not the true 
mechanism of the myocardial injury if any at all Mohammed & Januzzi, (2010). 
  Michos, et al. (2014) concluded that patients with CKD without suspected ACS, 
were associated with a worse prognosis when accompanied by elevated troponin levels.  
More research is needed in regarding the elevated troponin levels in patients with CKD 
and should focus on which biomarker is the most appropriate prognosticly for this patient 
population.  The possibility exists for the APRN to be immersed in this type of research 
which would help to increase current knowledge and to upgrade current evidence-based 
guidelines.  The APRN operates as a change agent to function as a leader, active member 
of the multidisciplinary team, and helping to institute measures that will improve overall 
outcomes with providing holistic care, discharge planning, follow up appointments, and 
the integration of technology in today’s high-tech world. 
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Appendix A 
Troponin Elevation in Chronic Kidney Disease Patients’ 
Pre-and Post-Test 
 
1.  What is your current level of education? 
      A. Associates Degree 
      B.  Diploma 
      C.  Bachelor’s Degree 
      D.  Master’s Degree 
2.  How many years have you been a Nurse? 
       A.  0-5 Years 
       B.  6-10 Years 
       C.  11-15 Years 
       D.  16-20 Years 
       E.  Over 20 Years 
3.  How is Chronic Kidney Disease (CKD) diagnosed?  Please Select All That Apply 
     A.  Serum BUN and Creatinine Levels 
     B.  Microalbumin level 
     C.  Complete Blood Count 
     D.  Fasting Blood Glucose 
     E.  Renal Ultrasound 
4.  What is the normal glomerular filtration rate of a healthy adult? 
      A.  > 60 ML/Min 
      B.  < 60 ML/Min 
      C.  < 40 ML/ Min 
      D.  > 50 ML/Min 
 
 
 
 
39 
 
5.  Which of the following are risk factors for Chronic Kidney Disease (CKD)? 
      A.  Hypertension 
      B.   Diabetes 
      C.   Cardiovascular Disease 
      D.  Familial History of CKD 
      E.  All the above 
6.  Which of the following are considered signs and symptoms of Acute Coronary 
Syndrome?       Please select all that apply. 
      A.  Chest Pain 
      B.  Dizziness or Lightheadedness 
      C.  Nausea 
      D.  Diaphoresis 
      E.  Dyspnea 
7.  Which of the following are NOT considered risk factors for ACS? 
       A.  Smoking 
       B.  Elevated Cholesterol 
       C.  Hypertension 
       D.  Abnormal Blood Glucose Level 
8.    Which of the following values is considered a normal troponin level? 
        A.   < 0.010 
        B.   < 0.03 
        C.    > 0.414 
        D.    > 0.003 
9.  Which of the following is a sign of Chronic Kidney Disease? 
      A.  Foaming, tea colored, bloody cloudy urine 
      B.  Lower Back Pain 
      C.  Low Grade Temperature 
      D.  Yellow colored straw like urine 
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10.  Which of the following are considered risk factors of Acute Coronary Syndrome?  
Select all that apply 
        A.  Hypertension 
        B.  Elevated cholesterol 
        C.  Obesity 
        D.  Smoker 
        E.  Diabetes 
11.  What does an elevated troponin in the presence of chronic kidney disease with no 
other cardiac symptoms such as chest pain, shortness of breath, nausea, vomiting, 
diaphoresis, epigastric pain, back pain, or jaw pain most likely indicate? 
       A.  Acute Myocardial infarction 
       B.  Pancreatitis 
       C.  Increase the risk of cardiac mortality 
       D.  Acute Coronary Syndrome 
12.  What would an elevated troponin in the setting of Acute Coronary Syndrome with 
symptoms to include chest pain, shortness of breath, nausea, vomiting, pain with 
radiation to the jaw, neck, back or epigastric area most likely indicate? 
      A.  a CKD flare up 
      B.  Require the need for immediate action to include monitoring and further          
diagnostic workup 
      C.  Discharge home with PCP follow up 
      D.  Hypertensive emergency  
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Appendix B 
CNO Support Letter 
 
September 20, 2017 
 
Dear Mr. Sasso, 
 
Thank you for your interest in enhancing the body of knowledge in emergency nursing 
and providing our staff with a voluntary opportunity to participate in nursing research. 
 
I am happy to endorse and support your efforts in this project and will be looking forward 
to participating in your research and seeing the outcomes of your education regarding 
patients with elevated troponin levels with chronic kidney disease without the presence of 
acute coronary syndrome.   Your efforts in this area are to be commended and are 
wholeheartedly supported. 
 
With best regards, 
 
Darcy Abbott, MS, RN, CEN 
Director of Emergency Services 
Associate Chief Nursing officer 
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Appendix C 
Kent IRB Letter 
 
 
 
 
Dear Mr. Sasso,   
 
 
 Thank you for your submission of the above-named project to the Kent 
Institutional Review Board. 
Dr. Jonathan Gates, Kent IRB Chair, has determined this project is not subject to 
Institutional Review Board regulations, as this is a Performance Improvement Project. 
Please retain a copy of this correspondence within your records. 
If you have any questions, please contact Donna Coppola, Kent Hospital IRB 
Coordinator at 401-7377010, extension 31879 or dmcoppola@carene.org. Please include 
your project title in all correspondence with this committee. 
Jonathan Gates, MD Kent IRB Chair
TO: David Sasso, Jr, BSN, RN 
FROM. Kent Hospital Institutional Review Board 
PROJECT TITLE: Troponin Elevation in Chronic Kidney Disease: An Educational Project 
SUBMISSION TYPE: Review 
ACTION: Determination of IRBNetlD 1142738 
DECISION DATE.  October 18, 2017 
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Appendix D 
Nurse Recruitment Letter 
February 10, 2018 
Dear Fellow Nurse, 
Hello, my name is David J Sasso Jr.  I am currently enrolled in the Master of Science 
program in Nursing at Rhode Island College.  You are being asked to voluntarily 
participate in an educational program about nurses’ knowledge of chronically elevated 
troponin levels in the setting of chronic kidney disease, and the absence of acute coronary 
syndrome.  This project is being conducted in conjunction with Dr. Debra Servello who 
serves as the primary investigator.  You have been identified as a possible participant 
because you are employed within the Emergency Department at Kent Hospital.   
 
The format for the education program will be a pre-test which should take no more than 
10-15 minutes of your time to complete.  The questions on the pre-test will assess your 
knowledge about elevated troponin levels in patients with chronic kidney disease without 
acute coronary syndrome.  The link embedded at the end of this letter will to take you to 
the online survey platform.   
 
An educational poster will be placed in the break room and educational pamphlet will be 
emailed to your work email with the hope that you will be able to take time out of your 
busy day to review the content.   
 
A link to the post test will be emailed to your work email two weeks after the 
informational pamphlet was sent. Results from the pre-test and post-test will be 
anonymous. Data will be reviewed to assess aggregate knowledge increase.  No 
individual data will be shared.   
 
Participation in this program is voluntary.  If you do participate you will be entered in a 
drawing for a gift card in the amount of $25.00.  Should you have any questions about 
this project, you may feel free to contact me directly via the means provided below, Dr. 
Debra Servello directly at dservello@ric.edu, 401-456-9611 or the Rhode Island College 
IRB at IRB@ric.edu.  Thank you for your time. 
 
Please click this link to be taken directly to the pre-test (Link Inserted Here). 
 
Sincerely,  
 
David J Sasso Jr, BSN, RN 
401-255-8003 
dsasso_2082@ric.edu 
Rhode Island College 
Kent Hospital Emergency Department Per Diem RN 
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Appendix E 
Email Script 
 
Hello, my name is David J Sasso Jr.  I am a graduate student at Rhode Island 
College.  Part of my curriculum requires that I complete a project. I have chosen to 
complete an informational program as my project.  I created this informational program 
in conjunction with the principle investigator Dr. Debra Servello which is geared towards 
emergency department nurses.  The project is called Troponin Elevation in Chronic 
Kidney Disease.      
 
The program will involve you taking a pre-test, reviewing of an informational 
pamphlet, and conclude with a post-test.  The pre-test will assess your knowledge about 
elevated troponins in patients with Chronic Kidney Disease.  The pre-test should take you 
no longer than 10-15 minutes to complete. Attached to this email is an informational 
letter which will provide more information about the project.  Please click the attachment 
to review the informational letter.  Should you decide to participate, clicking the link 
embedded in the informational letter will take you to the pre-test. 
 
A link to the post test will be emailed to your work email two weeks after the 
informational pamphlet was sent. Results from the pre-test and post-test will be 
anonymous. Data will be reviewed to assess aggregate knowledge increase.  No 
individual data will be shared.   
 
If you choose to participate, you will be entered in a drawing to receive a $ 25.00 
gift card.  Your participation is voluntary. Results will be anonymous.  
 
 
Thank you for taking the time to read this email, informational letter, and for your potential 
participation. 
 
 
Sincerely,  
 
David J Sasso Jr BSN, RN 
dsasso_2082@email.ric.edu 
Rhode Island College 
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Appendix F 
Elevated Troponin in Chronic Kidney Disease Program Information 
• Chronic kidney disease (CKD) affects more than 30 million Americans with 
many going undiagnosed (Centers for Disease Control and Prevention, 2017).   
• CKD is defined as having a decreased Glomerular Filtration Rate of less than 
60ml/min or the presence of elevated biomarkers that may indicate kidney 
damage for three months or greater (Ozieh, et al. 2017). 
• CKD Pathophysiology is best described as initial hyperfiltration that activates the 
RAAS (Renin Angiotensin Aldosterone System) which causes the protein-uria.  
Angiotensin II and protein uptake at the tubules causing inflammation and fibrosis 
of the glomerulus and the tubules.  This leads to a progressive decline in GFR and 
more systemic complications occur (Chaudry, 2012) 
• CKD risk factors include Diabetes, High Blood Pressure, Heart Disease, Familial 
History of CKD, and Obesity (CDC, 2017). 
• CKD signs and symptoms are generally nonspecific, and most people don’t feel 
ill at all (CDC, 2017).   
• Diagnosing CKD is accomplished by checking BUN, Creatinine, and 
microalbumin level in urine. A renal ultrasound may also be ordered. (CDC, 
2017). 
• Kidney damage is detected as excretion of urinary albumin of greater than 30 
mg/day or its equivalent (Rosenberg, 2016). 
• A decreased eGFR and increased proteinuria increase the risk of developing 
cardiovascular disease (Sarnack, Gibson & Henrick, 2015). 
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• Patients diagnosed with CKD present with traditional and nontraditional risk 
factors that contribute to the development of cardiovascular disease such as 
hypertension, smoking, diabetes, and elevated cholesterol levels (Sarnack, Gibson 
& Henrick, 2015). 
• Heart disease is the number one cause of death in the CKD patient population 
summating up to 50% of deaths Colbert et al., (2015). 
• Miller & Granger (2016) state that the chief complaint of chest pain is responsible 
for approximately 6 million annual visits to emergency departments in the United 
States.  Acute Coronary Syndrome (ACS) is responsible for 12 to 15% of those 
cases.   
• Risk factors for ACS include advancing age, elevated blood pressure, elevated 
cholesterol, cigarette smoking, lack of physical activity, unhealthy diet, diabetes, 
obesity, and known familial history of chest pain, heart disease or stroke. (Mayo 
Clinic, 2017) 
• ACS is a functional term applied to patients where there is an indication of 
myocardial ischemia or myocardial infarction. (Miller & Granger, 2016) 
•  ACS refers to a spectrum of clinical presentations ranging from ST-Segment 
elevation myocardial infarction (STEMI) to presentations commonly found in 
non-ST Segment elevation infarction (NSETMI) or unstable angina (Coven & 
Yang, 2016) 
• There are three different types of ACS: unstable angina, non-ST elevation MI, and 
ST segment elevation MI.  ST segment elevation and non-ST elevation MI, 
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diagnosable if elevated troponin levels are present, which will typically rise and 
fall before, during, and after an event. (Miller & Granger, 2016) 
• Patients experiencing ACS may describe their symptoms as palpitations, pain in 
the chest described as pressure, squeezing, or a burning sensation primarily in the 
precordium with potential radiation to the neck, shoulder, back, upper abdomen, 
or either arm.  Exertional dyspnea that resolved with pain or rest. Nausea, 
Vomiting, or profuse diaphoresis may also be complaints. (Coven & Yang, 2016) 
• Unstable angina is classified as myocardial ischemia with no elevation in 
biomarkers like troponin. (Miller & Granger, 2016) 
• The immediate focus should be on treatment, because early intervention leads to 
the best outcomes. (Miller & Granger, 2016)  
• Upon presentation to the emergency department, an initial 12 lead EKG should be 
obtained within ten minutes, and continuous telemetry monitoring initiated. (Miller 
& Granger, 2016) 
• Next, a history and physical exam to correlate with current signs and symptoms 
exhibited.  Laboratory tests should be ordered, to include troponin, electrolytes, 
bun, creatinine, and complete blood count. (Miller & Granger, 2016) 
• A chest x-ray is standard in this patient population, as it can be an asset with 
differential diagnosis. A risk stratification assessment of the patient presenting with 
these signs and symptoms is conducted. (Miller & Granger, 2016) 
• Troponin is the preferred biomarker to diagnose acute myocardial infarction 
which may or may not be present with presentation of ACS. (Januzzi & 
Mohammed, 2010) 
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• Troponin is a macromolecular complex that consists of three polypeptides closely 
intertwined and are actively related to the contraction of heart muscle. (Januzzi & 
Mohammed, 2010)   
• A normal troponin level is < 0.03 as referenced Januzzi & Mohommad, 2010 
• Michos (2014) Elevated troponin levels reveal an association of a worse 
prognosis in patients with CKD not experiencing ACS.  For patients with CKD 
with no indication of ACS, elevated troponin levels remain potent predictors of 
mortality, and currently support the current U.S. Food and Drug Administration 
position that measuring serum troponin levels is an appropriate risk stratification 
tool in this patient population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
